Special Issue "Prevention and Treatment of Bone Metastases from Breast Cancer"
A special issue of Journal of Clinical Medicine (ISSN 2077-0383).
Deadline for manuscript submissions: closed (31 July 2013)
Prof. Dr. Robert Coleman
Department of Oncology, Cancer Clinical Trials Centre, Academic Unit of Clinical Oncology, Broomcross Building, Weston Park Hospital, University of Sheffield, Sheffield, S10 2SJ, UK
Phone: +44 114 226 5213
Fax: +44 114 226 5364
Interests: cancer induced bone disease especially with relevance to breast cancer; the development of bone targeted agents in oncology, evaluation of bone markers in oncology to aid drug development and provide both prognostic and predictive information in the management of metastatic bone disease, and the assessment of adverse effects of cancer treatments on bone health and evaluation of various treatment strategies
Bone metastases are common in advanced breast cancer and cause considerable morbidity. They result from the interactions between cancer cells in the bone marrow microenvironment, haematopoietic stem cells and normal bone cells. Bone-targeted treatments may modify the course of the disease via inhibitory effects on this “vicious cycle” of growth factor and cytokine signalling between tumour and bone cells within the bone marrow micro-environment. Improvements in both disease free and overall survival in women with early breast cancer have been demonstrated with oral clodronate and in several large randomised adjuvant trials of zoledronic acid. The evidence for this is particularly strong in patients with low levels of reproductive hormones including premenopausal women receiving ovarian suppression therapy and those who have passed through menopause at the time of diagnosis. Bone-targeted agents, including bisphosphonates and denosumab, are an important component of management in advanced malignancy. Combined with systemic cancer therapy, effective symptom control and appropriate surgical and radiological interventions, modern multi-disciplinary care has transformed the care of patients with metastatic bone disease.
These reviews will cover the following important topics spanning clinical and translational cancer medicine:
- Mechanisms of metastasis
- Adjuvant therapy to prevent bone metastases
- Bone targeted treatments for the management of bone metastases
- Radiotherapy and radioisotopes for the treatment of bone metastases
- Imaging for diagnosis and monitoring of bone metastases
Prof. Dr. Robert Coleman
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed Open Access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. For the first couple of issues the Article Processing Charge (APC) will be waived for well-prepared manuscripts. English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
- breast cancer
- bone metastases
- RANK ligand
- adjuvant therapy
- treatment induced bone loss
- vitamin D
J. Clin. Med. 2014, 3(2), 521-536; doi:10.3390/jcm3020521
Received: 2 February 2014; in revised form: 3 March 2014 / Accepted: 14 March 2014 / Published: 9 May 2014| PDF Full-text (237 KB) | HTML Full-text | XML Full-text
Review: Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical Practice
J. Clin. Med. 2014, 3(1), 1-24; doi:10.3390/jcm3010001
Received: 9 November 2013; in revised form: 11 December 2013 / Accepted: 16 December 2013 / Published: 9 January 2014| PDF Full-text (732 KB) | HTML Full-text | XML Full-text
Review: Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian Guideline
J. Clin. Med. 2013, 2(4), 283-301; doi:10.3390/jcm2040283
Received: 9 November 2013; in revised form: 26 November 2013 / Accepted: 28 November 2013 / Published: 17 December 2013| PDF Full-text (227 KB) | HTML Full-text | XML Full-text
Review: The Roles of Epithelial-to-Mesenchymal Transition (EMT) and Mesenchymal-to-Epithelial Transition (MET) in Breast Cancer Bone Metastasis: Potential Targets for Prevention and Treatment
J. Clin. Med. 2013, 2(4), 264-282; doi:10.3390/jcm2040264
Received: 20 September 2013; in revised form: 25 October 2013 / Accepted: 8 November 2013 / Published: 22 November 2013| PDF Full-text (361 KB) | HTML Full-text | XML Full-text
Article: Can Zoledronic Acid be Beneficial for Promoting Tumor Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy?
J. Clin. Med. 2013, 2(4), 188-200; doi:10.3390/jcm2040188
Received: 16 August 2013; in revised form: 5 September 2013 / Accepted: 11 September 2013 / Published: 16 October 2013| PDF Full-text (274 KB) | HTML Full-text | XML Full-text
J. Clin. Med. 2013, 2(4), 176-187; doi:10.3390/jcm2040176
Received: 18 July 2013; in revised form: 7 August 2013 / Accepted: 10 September 2013 / Published: 14 October 2013| PDF Full-text (220 KB)
J. Clin. Med. 2013, 2(3), 136-150; doi:10.3390/jcm2030136
Received: 26 July 2013; in revised form: 20 August 2013 / Accepted: 10 September 2013 / Published: 23 September 2013| Cited by 1 | PDF Full-text (322 KB) | HTML Full-text | XML Full-text
J. Clin. Med. 2013, 2(3), 89-102; doi:10.3390/jcm2030089
Received: 12 June 2013; in revised form: 22 July 2013 / Accepted: 25 July 2013 / Published: 28 August 2013| PDF Full-text (567 KB) | HTML Full-text | XML Full-text
J. Clin. Med. 2013, 2(3), 67-88; doi:10.3390/jcm2030067
Received: 24 June 2013; in revised form: 25 July 2013 / Accepted: 29 July 2013 / Published: 19 August 2013| Cited by 1 | PDF Full-text (239 KB) | HTML Full-text | XML Full-text
Last update: 23 May 2013